Medicine Description bosulif 400 mg
Bosulif is an innovative medicine used to treat chronic myeloid leukemia (CML) in adults, a type of cancer that affects white blood cells. Bosulif contains an active ingredient called bosutinib, a tyrosine kinase inhibitor, which effectively inhibits the growth of cancer cells, providing patients with a better quality of life.
The active ingredient in Bosulif and its mechanism of action
Bosutinib: Bosutinib belongs to a class of tyrosine kinase inhibitors, which are medications that target specific proteins that play a role in the growth of cancer cells. Bosutinib works by inhibiting the BCR-ABL protein, the protein responsible for the growth of cancer cells in CML. By inhibiting this protein, Bosulif stops the proliferation of cancer cells, helping control the disease.
Indications and therapeutic uses of Bosulif
Bosulif is used in the following cases:
Treatment of chronic myeloid leukemia in the chronic, accelerated, or blast phase, in patients who have not responded to or are intolerant to other treatments, such as imatinib.
Bosulif is an effective treatment option for patients with genetic mutations that make them resistant to other treatments.
It is used when patients are intolerant to other treatments.
Available Concentrations of Bosulif on the Market and Their Variety
Bosulif is available in various strengths to meet the diverse needs of patients, including:
100 mg
400 mg
500 mg
These strengths are available in the form of coated tablets, making them easy to take and absorb.